Related Experiment Video

Updated: Aug 15, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized

Daphna Shefet1, Eyal Robenshtok, Mical Paul

  • 1Department of Medicine E, Beilinson Campus, Rabin Medical Center, Petah-Tiqva, Israel. dshefet@yahoo.com

Archives of Internal Medicine
|September 28, 2005
PubMed
Abstract

Insights

Empirical antibiotic coverage for atypical pathogens in community-acquired pneumonia does not improve survival or clinical outcomes. Limiting antibiotic spectrum may reduce toxicity, resistance, and costs.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Current guidelines recommend broad-spectrum antibiotics for community-acquired pneumonia (CAP) to cover atypical pathogens.
  • Evidence supporting the necessity of atypical pathogen coverage in CAP empirical treatment is insufficient.
  • Narrowing antibiotic spectrum may reduce adverse effects, antimicrobial resistance, and healthcare costs.

Purpose of the Study:

  • To assess the efficacy of empirical antibiotic coverage for atypical pathogens in hospitalized CAP patients.
  • To evaluate the impact on mortality, clinical success, and bacteriological eradication.
  • To determine if atypical pathogen coverage offers benefits over standard treatment.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Searched MEDLINE, EMBASE, and Cochrane Library for relevant studies.
  • Pooled relative risks (RRs) with 95% confidence intervals (CIs) using a fixed-effects model; primary outcome was all-cause mortality.

Main Results:

  • Included 24 trials with 5015 patients; most studies compared beta-lactams with quinolones/macrolides.
  • No significant difference in all-cause mortality between groups (RR, 1.13 [95% CI, 0.82-1.54]).
  • Atypical pathogen coverage showed a trend toward clinical success and bacteriological eradication, but this was lost in high-quality studies; advantage seen for Legionella pneumophila but not pneumococcal pneumonia. No difference in adverse events.

Conclusions:

  • Empirical antibiotic coverage of atypical pathogens in hospitalized CAP patients provides no survival or clinical efficacy benefit.
  • Current recommendations for broad-spectrum antibiotics in CAP may not be necessary.
  • Further research into de-escalation strategies for CAP treatment is warranted.

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.